Neurocrine Biosciences, Inc. develops and markets pharmaceutical products for neurological, psychiatric, and endocrine disorders. Its lead asset is INGREZZA, which treats tardive dyskinesia, and other products include ONGENTYS, ORILISSA, and ORIAHNN. The company has license and collaboration agreements with several pharmaceutical companies and is headquartered in San Diego, California.